TrialBreast cancer (Tokyo, Japan)2016

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

Eiichi Shiba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.